The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum - 6-8 December 2014 Alain PRAT, Technical Officer,

Slides:



Advertisements
Similar presentations
Armand Racine Consultant Chemicals Branch
Advertisements

POLAND Development Management System in Poland Brussels, 2 July 2010.
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
Towards a model M&E system for AIDS programs Kampala April
World Health Organization
The AU Model Law on Medical Products Regulation and Harmonisation
Children’s Social Care Workload Management System (WMS) A Two-fold approach DSLT 16 th November 2010 Updated with new SWRB standards.
RBM Communications Assessment Challenges and Opportunities in Ghana, Mali, Senegal, Tanzania and Uganda.
Agência Nacional de Vigilância Sanitária Second Latin American Congress of Clinical Research, Mexico City, September 29 – October 1,
Regulatory Body MODIFIED Day 8 – Lecture 3.
ICH-GCG June 2009 Pan American Health Organization CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): James Fitzgerald.
NATIONAL DRUG AUTHORITY - UGANDA | Slide 1 of February 2010, Geneva, Switzerland How the African NMRAs are benefiting from the WHO medicines prequalification.
EMERGING AND RE-EMERGING INFECTIOUS DISEASES: A CONTINUOUS CHALLENGE FOR EUROPE STOA - AVIESAN Workshop June 19th 2012, European Parliament, Bruxelles.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA. Presentation by: Dr. Joseph K. Yano B.Pharm (Nbi) L.L.B (Moi) Legal Officer Pharmacy and Poisons Board Ministry.
Report on the current legal structure and resources available to the environmental protection agencies and inspectorates in Croatia 1st BERCEN Exchange.
DPG HEALTH MEETING USAID CONFERENCE ROOM 6 NOVEMBER 2013 International Health Regulation (2005)
Module N° 8 – SSP implementation plan. SSP – A structured approach Module 2 Basic safety management concepts Module 2 Basic safety management concepts.
Regulatory Perspective on Development of
Cavendish Scott, Inc. 1 Regulatory and Statutory Compliance: It’s Everybody’s Business! Diana Lough Cavendish Scott, Inc.
And Pharmaceuticals Health Technology Technical Cooperation for Essential Drugs and Traditional Medicine Challenges of Medicine Regulation in Africa Global.
Assessments. Assessment in the Project Cycle DESIGN IMPLEMENTATION MONITORING EVALUATION ASSESSMENT.
SAHPRA proposals Nov 2009 A GLIMPSE OF WHAT SAHPRA IS INTENDED TO BECOME KEY PROPOSALS FOR SAHPRA NOVEMBER 2009 DR NICHOLAS CRISP.
1 A QUESTION OF BALANCE: DEALING FAIRLY WITH CLAIMS FOR MEDICINES Peter Folb Treatment Action Campaign 26 September 2006.
NRA in BTSs of the EMR Dr. Nabila E. Metwalli Regional Advisor / Blood Safety WHO / EMRO Cairo, Egypt and Dr. Abdel Aziz Saleh WHO / EMRO Advisor.
Third OIE Global Conference on Animal Welfare Kuala Lumpur, Malaysia The OIE PVS Pathway Dr. Mariela Varas OIE International Trade Department.
TWINNING LIGHT PROJECT RO2004/IB/OT-09 “Strengthening the market surveillance authorities regarding checks for conformity with the rules on product safety.
ACCESS TO MEDICINES - POLICY AND ISSUES
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Regulatory Authority.
Ratification of the United Nations Convention against Corruption in Lithuania A Review of the Compliance of the Lithuanian Legal and Institutional Framework.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Eurostat/UNSD Conference on International Outreach and Coordination in National Accounts for Sustainable Development and Growth 6-8 May, Luxembourg These.
International Atomic Energy Agency Roles and responsibilities for development of disposal facilities Phil Metcalf Workshop on Strategy and Methodologies.
Legal Framework and Structure. Public Internal Financial Control Strategy ( ) focuses on three activities Institution of a Centralized Harmonization.
WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies WHO Headquaters, Geneva, Switzerland 31 October - 4 November 2011 Alain PRAT, Technical.
Ministry of State Administration and Administrative Reform, Republic of Bulgaria 18 February 2008 Brdo, Slovenia 18 February 2008 Brdo, Slovenia Contribution.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.
Miriam Naarendorp Pharmacy Policy Coordinator & Head of the Pharmaceutical Inspectorate Coordinadora de la Politica Farmaceutica & Jefa de la Inspeccion.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
REPUBLIC OF ALBANIA PUBLIC PROCUREMENT AGENCY Eighth Regional Public Procurement Forum May, 22-25, 2012 Tirana
2010 James Fitzgerald Senior Advisor, Medicines and Health Technologies PAHO/WHO rd St Washington DC USA International Cooperation in Quality.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser Ministry of Health, ROMANIA.
1 M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 29 – Customs union Bilateral screening:
WORKSHOP ON ACCREDITATION OF BODIES CERTIFYING MEDICAL DEVICES INT MARKET TOPIC 6 CH 5 ISO MANAGEMENT RESPONSIBILITY Philippe Bauwin Medical.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
TAIEX-REGIO Workshop on Applying the Partnership Principle in the European Structural and Investment Funds Bratislava, 20/05/2016 Involvement of Partners.
Audit of predetermined objectives
GEF Familiarization Seminar
Alain PRAT, Technical adviser, QSM/EMP/HSS WHO - Geneva
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
Irena Prat and Josée Hansen World Health Organization
Medicines Control Council (MCC) &
Establishing the Infrastructure for Radiation Safety Preparatory Actions and Initial Regulatory Activities.
Dr Samvel Azatyan Technical Officer Regulatory Support
Jordan Food & Drug Administration
QUALITY DEVELOPMENT IN COLOMBIA AND LATIN AMERICAN
Institutional Framework, Resources and Management
Regulation of Medical Products & Patient Safety- A Narrative Review
Advisor – Radu Iacob General Secretariat of the Government
Medicines Control Council (MCC) &
Dr Manisha Shridhar Regional Advisor WHO-SEARO
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
A FRIENDLY REMINDER ON OTC DRUGS. DRUG REGULATIONS IN THE PHILIPPINES.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
GMP Legal Framework in Kyrgyzstan
Interconnection of good practices: from development to distribution
Presentation transcript:

The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer, RSS/EMP/HIS National Regulatory Assessment: Tool and methology

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 2 |2 | National Regulatory Authority An entity/organization in charge of the administration of the medicines regulation, including at least one of the following regulatory activities: –Issuing marketing authorization and dealing with variation; –Testing the Quality of products; –Monitoring adverse drug reaction and events; –Inspecting checking compliance of practices with applicable requirements and enforcement operations; –Licensing of manufacturers, wholesalers and distribution channels –Controlling medicines promotion and advertisement –Controling clinical trials including adverse reactions or events –Providing of medicines information and promotion of rational use of medicines;

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 3 |3 | National Regulatory System The institutional arrangements of the national and/or regional and/or local bodies/authorities in charge of implementing and supervising the medicines regulation –Department in the Ministry of Health; –Specialized Agency; –Regional authority –Pharmacy Board; –Quality control laboratories; –Pharmaceutical council –…

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 4 |4 | Why an assessment tool ? To provide for documented evidence on the current situation regarding the medicines regulation and its implementation by identifying strengths and weaknesses To make recommendations on identified gaps for improvement To use assessment results as a input to develop a plan of actions for the NRA In line with one of the MRS strategic objectives –To strengthen National Regulatory Authorities (NRAs) capacities

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 5 |5 | National Regulatory System Cartography of the authorities MoH Ministry of Health Agency or Board Regional Authority Prof. Council Ethics Committees Reg. Entities Customs Aut. Police & Courts Local Authorities PhV Cent. Qual. Cont.Lab Nat. ECs *Conformity Assessment Body Ports of entry

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 6 |6 | National Regulatory Authority Cartography of the processes Management Regulatory Services & Products * Support Licensing of manufacturers, importers and distributers Authorizing the marketing of pharmaceutical products Performing regulatory inspection and enforcement activities Performing quality control testing on products Monitoring adverse drug reactions Quality Human Ress. Information Tech.Finance Communication StrategyGovernancePlanificationAccountability

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 7 |7 | NRA Assessment strategy Guidelines Operating procedures Templates Decret / Regulation Legislation / Act Regulatory pyramide Top Down Decisions Records

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 8 |8 | NRA Assessment methodology Not based on impressions, feelings or any subjective considerations Based on objective evidence of the existence, the implementation and the results Evidence collected through interviews should, whenever possible, be confirmed by more objective means Possible deficiencies or gaps should be thoroughly investigated and validated Consensus should be reached at the end with NRA

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 9 |9 | NRA Assessment Tool Design Module for reviewing the institution / 1 Legal basis Governance & Organizational structure Strategic planning Quality & Risk management system Management of finances (Fees) Management of human resources Partnership and collaboration

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 10 | NRA Assessment Tool Design Module for reviewing the institution / 2 Independence and impartiality Transparency and confidentiality Management of committees and external expertise Management of infrastructure and equipment Knowledge and IT Management Monitoring and accountability Communication

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 11 | NRA Assessment Tool Design Generic format for assessing regulatory functions Legal basis (Act, Regulation or statutory instruments) Guidelines, Norms and Standards Procedures and records Human and other Resources Decisions and others outputs Outcomes

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 12 | Limited number of indicators Example : Is there any guidelines on medicine registration? NRA Assessment Tool – Granularity / 1

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 13 | Increased number of indicators on the same subject Example : Is the guidelines dealing with the following aspects: Administrative part, Quality part, Safety part, Efficacy part, Product Information Ad Qu Sa EfPI NRA Assessment Tool – Granularity / 2

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 14 | References used as a basis for NRA Assessment Consolidated regulatory framework developed by WHO in various guidelines and books –Based on WHO National Drug Regulatory Legislation published in WHO TRS N°885 Consolidated a list of norms, standards and guidelines which should be (ideally) implemented –WHO, ICH, GHTF, ISO and Others

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 15 | NMRA assessments in AFRO region No

Alain PRAT, Regulatory System Strengthening EMP/HIS WHO/HQ Geneva 16 | Thanks for your attention